Transcranial Pulsation Shows Promise in Alzheimer’s, Other Neurological Conditions

VIENNA – Transcranial pulsation (TPS),⁣ a non-invasive brain⁢ stimulation technique, is gaining traction as a potential therapy for Alzheimer’s disease and other neurological disorders. The method, which utilizes low-energy shock waves, has been under development and research for three decades, initially focusing on alzheimer’s dementia. Recent studies and⁣ practical applications suggest promising⁣ results in treating Parkinson’s disease, depression, autism, and ADHD.

Growing Evidence ⁤supports ⁣TPS Therapy

With over 15,000 patients treated and nearly 80⁢ specialized clinics in German-speaking countries, TPS is becoming⁣ increasingly⁤ recognized. A recent study from⁤ the Medical University of⁣ Vienna adds to ⁤the growing body of scientific data supporting TPS. Doctors report that TPS can slow the progression of neurodegenerative diseases like Alzheimer’s, improve symptoms, and enhance patients’ independence and quality of life.

How transcranial Pulsation Works

TPS delivers targeted shock wave impulses through the skull into the brain. ‍These impulses stimulate blood circulation, promote the release of growth-promoting messenger substances, activate nerve cells (neurons), and encourage synapse formation (connections ⁣between neurons). This process can‍ potentially slow down degenerative processes in the brain. Each treatment session is painless, lasts approximately 30 minutes, and is conducted on an ⁣outpatient basis with minimal side effects.

Research and⁣ Recognition

TPS has⁢ been researched at institutions such ⁤as the University Hospital Bonn, the German Center for Neurodegenerative Diseases (DZNE), and the Wahrendorff Clinic in Hanover. Over 50 scientific studies and⁣ specialist publications have explored‍ the mechanisms of action, patient safety, and the lack of notable⁤ side effects associated with this shock wave method.While the primary focus remains on Alzheimer’s dementia, research is expanding⁣ to include Parkinson’s, depression, autism, and ADHD.

The “Medical Interest Group TPS,” a‍ collaboration‍ of specialists, considers TPS a relevant therapy ⁤on its way to⁤ becoming an evidence-based treatment for Alzheimer’s dementia.

Vienna Study Highlights Effectiveness

A double-blind, placebo-controlled⁣ study at the Medical University of Vienna examined the effects of TPS on 60 Alzheimer’s patients. Results indicated that individuals under 70 experienced significant improvements in memory and cognitive skills. Symptoms of depression, frequently enough impacting the quality of life for Alzheimer’s patients, also decreased.‍ MRI scans revealed that TPS can activate key brain regions responsible for memory and attention.

Researchers used internationally recognized survey instruments,such as the Cerad Plus and the BDI-II,adhering to methodological standards of clinical research. Long-term data is also ⁢becoming more meaningful as doctors document positive effects lasting for⁣ months after treatment.

TPS as Part ⁣of a New Era in Medicine

TPS is part of a growing category of non-invasive brain stimulation (NIBS) ⁣techniques. Unlike drug therapies, NIBS relies on physical principles, using⁤ targeted stimuli to initiate neurobiological processes in the brain. Transcranial magnetic stimulation ⁢(TMS), primarily used for‍ depression, is another NIBS method included in official guidelines. While TMS uses electrical flows over⁢ magnetic fields,TPS employs low-energy shock wave impulses to reach deeper cerebral areas,making it suitable for treating Alzheimer’s and Parkinson’s.

NIBS methods work directly in the brain without straining the organism, where medication may have limitations. TPS has rare and mild side effects, such as headaches, restlessness, or tiredness, which typically subside⁣ quickly. The treatment is painless and does‍ not restrict patients’ ⁤daily activities.

Cost Considerations

While TPS is available in numerous ⁤specialist centers, statutory health insurance companies have‍ yet to cover the costs. This also applies to ‍TMS,despite its inclusion in official guidelines. The field of brain stimulation is relatively new and not⁤ yet fully integrated into performance catalogs, requiring time ⁢to overcome bureaucratic hurdles.

Though, some private health insurance companies⁢ are recognizing the potential of TPS and covering costs after ⁣individual assessments. By ⁣helping patients with Alzheimer’s disease live independently and actively, TPS may reduce the need for nursing ⁤home care and lower overall healthcare costs. Lecanemab,a recently approved medication in Europe,costs approximately⁢ $26,500 per year per patient,is limited to a small patient group,requires‍ intravenous governance,and carries risks of serious side effects necessitating regular MRI monitoring. TPS offers a lower-risk, outpatient choice with growing evidence of effectiveness.

Why Isn’t ⁤TPS More Widely Known?

Medical progress often takes time. New processes ‍face bureaucratic obstacles, limited visibility, and skepticism compared to established or pharmacological treatments.While TPS has gained traction among innovative neurologists and psychiatrists, it has yet to achieve widespread ⁤public awareness, partly due to ⁤limited media coverage.

Initiatives Promote facts and Awareness

Organizations like the “Medical Interest Group TPS” ⁤are working⁤ to increase awareness⁣ and provide information. These groups aim to report objectively about TPS, make scientific work accessible to the public, and keep patients and relatives informed. They also offer thorough‍ information about various forms⁢ of⁢ dementia, innovative therapies, neuroscience research, and practical strategies for preventing neurophysiological diseases.

The ⁣future of medicine will‍ likely involve physical principles that activate the brain, alongside chemical substances. TPS represents a part of this new era, offering a potentially valuable treatment option for individuals with neurophysiological diseases.